Highlights

1. Biocentis has engineered the most effective insect control solution ever developed for the $150B pest control market, delivering 95-100% suppression in target zones, which could facilitate an 80% reduction in pesticides use. 

2. We are joining world leading early-stage supporters: the Gates Foundation, European Union, Wellcome Trust, Grantham Foundation and Italy’s Algebris Climatech Fund. 

3. There’s a key 2nd mover advantage, inferior rival genetic solutions have spent the last 10 years educating and securing approval from regulators and establishing a commercial market, which has de-risked our approvals and the market entry process 

4. The team is comprised of leading scientists, entrepreneurs, and pest control executives. The head of development Kevin Gorman is an entomologist with 30+ years of industry experience and the former Chief Development Officer of our nearest rival. He spent 12+ years taking them from the lab through regulator education to scaling commercial sales. 

5. They have developed proprietary AI and automation solutions that enable greater profit margins, ability to scale quicker, and superior solution planning for insect release schedules, quantities, and placement to maximize suppression. 

6. By 2030, their proprietary genetic approach will see them reliably releasing 1 to 2 new products each year for different species, something rivals are unable to do and enabling them to be the first broad based genetic pest control platform.  

7. The timing couldn’t be better, as venture investment and market adoption of pesticide alternatives is growing rapidly. The increase in pest tolerance for insecticides is leading to decreased effectiveness at the same time that the build-up of toxicity in the environment is increasing public health impacts and liability claims. Biocentis eliminates negative public health, biodiversity, and broad environmental impacts.  

Company Status 

Built on $170M of validated research from Imperial College London backed by the Gates Foundation, Biocentis has secured the exclusive license to use of this technology across all insect species except those mosquitos that carry malaria. Support from the founders, EU, Wellcome Trust, Italy, and others have helped to establish business offices in the UK, and a world class R&D facility in Italy that gives a cost advantaged base of operations. The company’s first 2 products— 

1. Aedus Aegypti mosquito vector for dengue, zika, yellow fever, chikungunya, etc.  

2. Drosophila Suzukii fruit fly that destroys high-value berry, cherry, and plum crops  

—enter regulatory review in 2026 and commercial sales in 2029. The next 2 products will start development in 2026, with commercial sales expected in 2030.  

The first target markets have been Brazil and the US, because they have experience approving rival solutions and they alone represent a $2.1B market for these first two products. The in September the UK government awarded a €440k grant to support an accelerated regulatory approval process in the UK for the Drosophila Suzukii fruit fly, which will likely accelerate commercial sales of this product and enhance global reciprocal regulatory approvals.   

Investment Offering 

This investment represents the final chance to invest at a €28M pre-money valuation before multiple value inflection points. This round’s lead investors are the Grantham Foundation Algebris Climatech Fund, who are each investing €3.5M. The Grantham Foundation has endowed biotech research at Imperial College London and, along with the Wellcome Trust, are known for their exhausting technical due diligence of early-stage deep tech. The company projects achieving over €850M in revenue over the next 10 years, which translates into an €8B+ IPO valuation using a very conservative 10x multiple for a business driven by recuring sales. This leads us to project a >200x return for our syndicate. 

We are accepting up to $1,500,00 or €1,250,000 if preferred by the end of November from syndicate members who wish to participate in this exceptional opportunity. 

The Story  

The Biocentis Advantage, Exceptional Profits Meet Transformational Impact  

The company has developed the world's most advanced gene drive technology, which enables the passing on of a trait to 100% of offspring. This delivers near total seasonal suppression of pests, 95-100%, within the targeted zones compared to less than 65% for pesticides and 85-90% for the best current alternatives. Male insects are selected which are most desirable to females. They are modified in 2 ways that make 1) the eggs of their female offspring unviable and 2) the eggs of their male offspring unviable.  

In the lab, males can be treated to suppress the male infertility trait, which has 2 tremendous benefits. One, it enables very efficient rearing of the male insects (the product), because the challenging process of manual sex segregation is not necessary. Two, when the treated product is released into the wild, the male insects mate with wild females in very high percentages and produce more genetically modified males but no females.  The modified male offspring then mate in very high percentages with wild females and produce no viable eggs, thereby eliminating the product from the environment.   

This two-generation self-limiting feature enables Biocentis to control: 

• the temporal (time domain) impacts through the release schedule of the product, as the lifespan of the insects is reliably short; 

• the geographic concertation of impacts, as insects only travel so far over their lifetime; and 

• the risk of spreading genetically modified organisms in unintended ways, because they are inherently infertile. 

Perfect Market Timing Creates Unprecedented Opportunity 

The chemical pesticide industry is experiencing a perfect storm of declining efficacy, growing hostility, and increasing regulatory restrictions. With over $1.3B in venture capital already invested in pesticide alternatives and biological solutions capturing 31% of new crop protection patents, the market is primed for Biocentis' superior technology. Their self-limiting approach addresses the key regulatory and environmental concerns that have historically limited genetic solutions, providing a clear path to widespread adoption. 

World-Class Technology Platform and Intellectual Property 

Biocentis holds exclusive licensing rights to a comprehensive patent portfolio covering the foundational mechanisms of the world's most advanced gene drive system. Their proprietary AI platform enables 4.5-year species development cycles versus competitors' ~10 years, targeting conserved genetic pathways that allow rapid portfolio expansion across multiple insect species. This technological superiority, combined with their proprietary operational facility and complete scientific team, creates an unassailable competitive moat. 

Proven Team and Institutional Validation 

The company combines the world's leading genetic control scientists—the original inventors of the technology—with industry veterans who have successfully scaled biotech solutions through complex regulatory processes. This exceptional team has secured validation from premier institutions: the Wellcome Trust committed €5.12M over four years, while the Gates Foundation provided most of the initial $170M research foundation. Now the highly regarded Algabris Climatech Fund and Grantham Foundation are co-leading this round. Taken together this demonstrates broad institutional confidence in both the technology and commercial execution. 

Compelling Financial Projections with Built-in Downside Protection 

Biocentis projects exceeding €800M in revenue by 2035, which would equate to a greater than €8B valuation. More importantly for risk-conscious investors, the company's world-leading technology platform represents €1B+ strategic value to major agtech acquirers once even just two commercial products are in early market phases. This provides extraordinary downside protection. Today's €28M pre-money investment could see value appreciation to €1B+ within five years, representing potential 35x returns before the company reaches full market penetration. 

Exclusive Investment Opportunity with Limited Availability 

This seed round represents the final external investment opportunity before major value inflection points begin with field trials in 2026-2027. Market Impact Capital's involvement in this highly selective round is based on our strategic value in developing their go-to-market approach in Southeast Asia. With a hard deadline of November 19th for investor commitments and funding expected by November 27th, this represents the last opportunity to invest at this attractive entry valuation. 

For sophisticated investors seeking exceptional risk-adjusted returns in a transformational technology platform, Biocentis offers the rare combination of massive profit potential, institutional validation, and robust downside protection in a market poised for disruption.